CAR T-Cell Therapy – Pipeline Insights – 2018

SKU: DM937 | Last Updated On: Jun 22 2022 | Available Formats

In May 2019, the FDA granted orphan drug designation to Poseida Therapeutics’ P-BCMA-101 for the treatment of relapsed and/or refractory multiple myeloma.

CAR T-cell Therapies

01: Executive Summary

 

02: Scope of the Report

 

03: Introduction

3.1 CAR T-cell Therapies – Overview

3.2 CAR T-cell Therapies –Role in the treatment of various types of tumors

 

04: CAR T-cell Therapies – Pipeline Landscape

4.1 Overview of Pipeline CAR T-cell Therapies

4.2 CAR T-cell Therapies Filed and Phase III Products

4.3 Comparative Analysis

4.4 CAR T-cell Therapies Phase II Products

4.5 Comparative Analysis

4.6 CAR T-cell Therapies Phase I and IND Filed Products

4.7 Comparative Analysis

4.8 CAR T-cell Therapies Discovery and Pre-Clinical Stage Products

4.9 Comparative Analysis

4.10 CAR T-cell Therapies – Discontinued Products

4.11 CAR T-cell Therapies – Dormant Products

 

05: CAR T-cell Therapies by molecule type

5.1 Small molecule

5.2 Gene Therapies

5.3 Others

 

06: Comparative Analysis of Marketed and Pipeline CAR T-cell Therapies

 

07: Key Pipeline Product Profiles

 

08: Competitive Landscape

8.1 Prominent Vendors:

8.1a Celgene

8.2 Other Prominent Vendors:

8.2a Aeon Therapeutics

8.2b Autolus

8.2c Bellicum

8.2d Beijing Immunochina

8.2e Celyad

8.2f Eureka

8.2g Juno

8.2h Kite

8.2i Intrexon

8.2j Marino Biotechnology

8.2k Pinze Lifetechnology

8.2l Shanghai Unicar-Therapy

8.2m Sinobioway cell Therapy

8.2n Sirtex Medical

8.2o Ziopharm

 

09: Key News

9.1 Major Mergers and Acquisitions

9.2 Product News (including clinical trial progression updates)

 

 

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest